Targeted Therapy for Cancer: The Complete Guide to Precision Cancer Treatment

Targeted Therapy for Cancer
July 2026 Dr. Abhinav Narwariya 12 Min Read

Targeted Therapy for Cancer: The Complete 2026 Guide to Precision Cancer Treatment

Targeted therapy is a cancer treatment that attacks the specific genetic mutations or proteins driving a tumor’s growth, instead of destroying all fast-dividing cells the way chemotherapy does. It requires biomarker or genomic testing to identify the tumor’s molecular “target” before treatment begins, which is why it’s also called precision oncology or molecular-targeted therapy.

Below, Dr. Abhinav Narwariya, Senior Consultant and Unit Head of Medical Oncology at Max Hospital, Shalimar Bagh, Delhi, breaks down how targeted therapy works, which cancers respond best, what the latest survival data shows, and a practical framework patients and caregivers can use to find out if they qualify.

What Is Targeted Therapy?

Targeted therapy is a class of cancer drugs designed to interfere with specific molecules — usually proteins — that cancer cells need to grow, divide, or spread. Unlike traditional chemotherapy, which affects all rapidly dividing cells in the body, targeted drugs are built torecognize a precise mutation, receptor, or signaling pathway that is active mainly in cancer cells.

How Targeted Therapy Differs from Chemotherapy

This precision is what separates targeted therapy from older treatments.

Feature Chemotherapy Targeted Therapy
Mechanism Kills fast-dividing cells broadly Blocks a specific mutation or protein
Testing Required Not usually Yes — genomic / biomarker testing
Side Effect Pattern Hair loss, nausea, immune suppression Skin, blood pressure, or organ-specific effects tied to the target
Patient Selection Broad Narrow, biomarker-defined subgroup
Example Drugs Cisplatin, Paclitaxel Osimertinib, Trastuzumab, Olaparib

How Targeted Therapy Works: The Biology in Plain Language

Every cancer starts with a change inside a cell's DNA. Some of these changes create an "on switch" that gets stuck in the on position, telling the cell to divide endlessly. Targeted therapy drugs are designed to sit on that switch and jam it.

Three broad categories dominate clinical use today:

Small-Molecule Inhibitors

(Tyrosine Kinase Inhibitors / TKIs)

Oral drugs that block enzymes driving tumor growth signals from inside the cell.

Monoclonal Antibodies

Lab-made proteins that attach to targets on the outside of the cancer cell, blocking growth signals or flagging the cell for immune destruction.

PARP Inhibitors

DNA-Repair Blockers

Drugs that exploit a tumor's inability to repair its own DNA, common in BRCA-mutated cancers.

Real-World Examples of Targeted Therapy in Action

EGFR-Mutant Lung Cancer

Osimertinib and earlier-generation EGFR inhibitors target the EGFR mutation found in a meaningful subset of non-small cell lung cancer patients, particularly non-smokers with adenocarcinoma. This mutation was first linked to drug response in 2004, opening the door to the modern era of lung cancer precision treatment.

HER2-Positive Breast Cancer

Trastuzumab and related HER2-targeted antibodies changed outcomes for the roughly 15–20% of breast cancers that overexpress the HER2 protein.

BRCA-Mutated Ovarian and Breast Cancer

PARP inhibitors such as olaparib exploit BRCA1/2 mutations, offering an option specifically for patients who test positive on genetic panels.

ALK-Positive Lung Cancer

ALK inhibitors have moved this once-difficult-to-treat subtype into a chronic, manageable disease for many patients.

BCR-ABL-Positive Chronic Myeloid Leukemia

Imatinib and successors turned a once-fatal leukemia into a condition many patients now manage long-term with a daily pill.

The Statistics That Matter in 2026

Targeted therapy and precision oncology continue to transform cancer treatment, improving survival rates and expanding treatment options for patients worldwide.

70%

Overall Five-Year Survival

Overall five-year relative survival across all cancers combined has climbed to roughly 70% for patients diagnosed between 2015 and 2021, up from about 49% in the mid-1970s.

35%

Metastatic Melanoma

Five-year survival has more than doubled over the past 25 years, improving from around 16% to roughly 35%, driven by immune checkpoint inhibitors and targeted BRAF/MEK combinations.

22%

Liver Cancer Survival

Liver cancer survival has risen from approximately 3% to 22%, representing one of the largest relative gains among cancer types.

The Biggest Barrier Isn't Always the Drug

Access remains uneven. Asian, Black, and Hispanic patients are consistently less likely to receive the genetic testing required to qualify for targeted therapy. For many patients, the greatest barrier is not the treatment itself, but completing the diagnostic testing needed before treatment begins.

Precision diagnostics—including liquid biopsy, spatial transcriptomics, and AI-assisted pathology—are increasingly being used to match the right drug to the right patient faster than tissue biopsy alone allowed a decade ago.

"In my practice, the single biggest factor that determines whether a patient benefits from targeted therapy isn't the drug itself—it's whether biomarker testing was done early enough to guide the first treatment decision."
Dr. Abhinav Narwariya
Senior Consultant & Unit Head, Medical Oncology
Max Super Speciality Hospital, Shalimar Bagh, Delhi

Who Is a Candidate for Targeted Therapy?

Not every cancer, and not every patient, has an actionable target. Eligibility for targeted therapy depends on several important clinical factors.

1. Cancer Type

Lung, breast, colorectal, ovarian, certain leukemias/lymphomas, kidney, and melanoma currently have the most established targeted therapy options.

2. Molecular Testing Results

A mutation, gene fusion, or protein overexpression must be confirmed through tissue biopsy, liquid biopsy, or a comprehensive genomic panel.

3. Stage & Treatment History

Targeted therapy may be used during first-line metastatic treatment or after surgery, depending on the cancer type, stage, and approved treatment protocols.

4. Overall Health & Organ Function

Since targeted therapies have their own class-specific side effects, doctors also evaluate heart, liver, kidney function, blood pressure, and overall fitness before treatment.

Dr. Narwariya's Actionable Framework: The 4-Step "TARGET" Approach

To help patients and families navigate this decision without getting lost in medical jargon, Dr. Abhinav Narwariya recommends the following four-step approach.

01

Test Before You Treat

Request comprehensive biomarker or next-generation sequencing (NGS) testing at diagnosis—not just after chemotherapy fails. For many cancers, this single step determines eligibility for an entire category of targeted treatment.

02

Ask About Actionable Mutations

Don't just ask if a mutation was found. Ask which specific biomarkers were tested, including EGFR, ALK, ROS1, BRAF, HER2, BRCA1/2, KRAS, and NTRK, and whether approved or clinical trial targeted therapies are available.

03

Review the Evidence

Some targeted therapies have decades of clinical evidence supporting improved survival, while others are newer. Discuss the evidence behind your recommended treatment with your oncology team.

04

Plan for Monitoring & Resistance

Cancer cells can develop resistance over time. Ask your doctor about monitoring, repeat molecular testing, and the next-line treatment strategy if the initial targeted therapy stops working.

Targeted Therapy vs. Immunotherapy vs. Chemotherapy

Although all three treatments are used to fight cancer, they work in different ways and are recommended for different patients depending on the type of cancer and its molecular characteristics.

Question
Targeted Therapy
Immunotherapy
Chemotherapy
What it attacks A specific mutation or protein that drives cancer growth. The immune system's ability to recognize and destroy cancer cells. Rapidly dividing cells throughout the body, including cancer cells.
Testing Needed First? Yes
Biomarker or genomic testing is usually required. 		Sometimes
Tests such as PD-L1 may be recommended. 		No
Usually does not require biomarker testing.
Best Suited For Cancers with known driver mutations or molecular targets. Cancers with a high mutation burden or specific immune markers. Broad use across many cancer types.
Typical Side Effects Skin rash, high blood pressure, liver or organ-specific effects. Immune-related inflammation affecting organs. Hair loss, nausea, vomiting, fatigue, and low blood counts.

Frequently Asked Questions

Get answers to common questions about breast cancer diagnosis, treatment and consultation.

No. Targeted therapy blocks a specific cancer-driving mutation or protein directly, while immunotherapy works by helping the patient’s own immune system recognize and attack cancer cells. The two are sometimes combined.

For some cancers, especially certain leukemias, targeted therapy can lead to long-term remission. For many solid tumors, it extends survival and controls disease rather than curing it outright, though outcomes continue to improve each year.

Qualification depends on biomarker or genomic testing results specific to your cancer type. Ask your oncologist whether comprehensive molecular testing has been done and which actionable mutations were checked.

Side effects vary by drug class but often include skin rashes, high blood pressure, fatigue, and liver enzyme changes — generally different from, and often milder than, classic chemotherapy side effects, though this varies by patient.

Yes. Major cancer centers in India, including Max Hospital, Shalimar Bagh, offer biomarker testing and accessto approved targeted therapies across lung, breast, colorectal, and blood cancers, in line with international treatment protocols.

The Bottom Line

Targeted therapy has moved precision oncology from a research concept to standard practice for a growing list of cancers. The gains in survival—particularly for melanoma, certain lung cancers, and blood cancers—are real and measurable. However, targeted therapy is only effective when the right biomarker testing is performed at the right time.

Dr. Abhinav Narwariya's TARGET Framework emphasizes that the biggest gap in cancer outcomes today is often diagnostic rather than pharmacological. Patients who undergo comprehensive molecular testing early have significantly more treatment options than those who begin treatment before appropriate biomarker evaluation.

Medical Disclaimer

This article is intended for informational and educational purposes only. It should not replace individualized medical advice, diagnosis, or treatment. Always consult a qualified medical oncologist to determine whether targeted therapy is appropriate for your specific diagnosis and treatment plan.

Dr. Abhinav Narwariya

About the Expert

Dr. Abhinav Narwariya

Senior Consultant & Unit Head – Medical Oncology

Dr. Abhinav Narwariya is a Senior Consultant and Unit Head in the Department of Medical Oncology at Max Super Speciality Hospital, Shalimar Bagh, Delhi. He specializes in precision oncology, biomarker-guided cancer treatment, targeted therapy, immunotherapy, and personalized cancer care.

Book an Appointment
Document